Triumeq Pd is a drug owned by Viiv Healthcare Co. It is protected by 4 US drug patents filed from 2022 to 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 08, 2030. Details of Triumeq Pd's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | |||
| US8129385 | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Oct, 2027
(3 years from now) | Active |
| US9242986 | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Dec, 2029
(5 years from now) | Active |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US8129385 (Pediatric) | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Apr, 2028
(3 years from now) | Active |
|
US9242986 (Pediatric) | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Jun, 2030
(5 years from now) | Active |
FDA has granted several exclusivities to Triumeq Pd. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Triumeq Pd, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Triumeq Pd.
Exclusivity Information
Triumeq Pd holds 2 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2026. Details of Triumeq Pd's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 15, 2026 |
| Pediatric Exclusivity(PED) | Dec 15, 2026 |
Several oppositions have been filed on Triumeq Pd's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Triumeq Pd's generic, the next section provides detailed information on ongoing and past EP oppositions related to Triumeq Pd patents.
Triumeq Pd's oppositions filed in EPO
Triumeq Pd has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 28, 2014, by Ahrens, Gabriele. This opposition was filed on patent number EP06758843A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP17195280A | Feb, 2020 | Gilead Sciences, Inc. | Opposition rejected |
| EP16154531A | Dec, 2018 | Gilead Sciences, Inc. | Patent maintained as amended |
| EP06822311A | Nov, 2016 | Zwicker Schnappauf & Partner PartG mbB | Opposition procedure closed |
| EP06758843A | May, 2014 | Ahrens, Gabriele | Opposition procedure closed |
US patents provide insights into the exclusivity only within the United States, but Triumeq Pd is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Triumeq Pd's family patents as well as insights into ongoing legal events on those patents.
Triumeq Pd's family patents
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Generic Launch
Generic Release Date:
Triumeq Pd's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jun 08, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Triumeq Pd Generics:
There are no approved generic versions for Triumeq Pd as of now.
How can I launch a generic of Triumeq Pd before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Triumeq Pd's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Triumeq Pd's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Triumeq Pd -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 60 mg/5 mg/30 mg | 31 Mar, 2023 | 1 | 08 Dec, 2029 |
About Triumeq Pd
Triumeq Pd is a drug owned by Viiv Healthcare Co. Triumeq Pd uses Abacavir Sulfate; Dolutegravir Sodium; Lamivudine as an active ingredient. Triumeq Pd was launched by Viiv Hlthcare in 2022.
Market Authorisation Date:
Triumeq Pd was approved by FDA for market use on 30 March, 2022.
Active Ingredient:
Triumeq Pd uses Abacavir Sulfate; Dolutegravir Sodium; Lamivudine as the active ingredient. Check out other Drugs and Companies using Abacavir Sulfate; Dolutegravir Sodium; Lamivudine ingredient
Dosage:
Triumeq Pd is available in tablet, for suspension form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 60MG BASE;EQ 5MG BASE;30MG | TABLET, FOR SUSPENSION | Prescription | ORAL |